RECOVER-SLEEP: Platform Protocol, Appendix_B (CPSD)
Launched by DUKE UNIVERSITY · May 6, 2024
Trial Information
Current as of July 21, 2025
Recruiting
Keywords
ClinConnect Summary
The RECOVER-SLEEP trial is studying ways to help people with Long COVID who are experiencing sleep problems. Specifically, it looks at different treatments that could improve sleep issues caused by this condition, which can include feeling overly sleepy during the day or having trouble sleeping at night. The trial is designed to test various methods and see which ones work best for different types of sleep disturbances in patients recovering from COVID-19.
To join the trial, participants should be aged 65 and older and meet certain health criteria. Some individuals may be excluded if they have severe vision problems or if they are taking specific sleep medications and aren’t willing to stop them for a month before starting the study. Those who participate can expect to receive targeted treatments designed to improve their sleep, and they will be monitored throughout the study to assess how well these treatments are working. It's an exciting opportunity to help researchers learn more about improving sleep for those affected by Long COVID.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • • See NCT06404086 for RECOVER-SLEEP: Platform Protocol level inclusion criteria which applies to this appendix
- Exclusion Criteria:
- • • See NCT06404086 for RECOVER-SLEEP: Platform Protocol level exclusion criteria which applies to this appendix
- Additional Appendix B (CPSD) Level Inclusion Criteria:
- • The following additional exclusion criteria are to be considered together for determining eligibility. They are separated here by TL and melatonin only for presentation. RESET-PASC presents no additional exclusions.
- • TAILORED LIGHTING EXCLUSION CRITERIA
- • 1. Severe visual impairments affecting sensitivity or ability to respond to light
- • 2. Severe photosensitivity dermatitis
- • 3. Severe progressive retinal disease, eg, macular degeneration
- • 4. Permanently dilated pupil, eg, following certain cataract surgeries
- • 5. Unwilling to remove or not wear blue-light-blocking glasses during TL dosing
- • MELATONIN EXCLUSION CRITERIA
- • 1. Sleep medication, if not willing to washout for 4 weeks.
About Duke University
Duke University, a leading academic and research institution located in Durham, North Carolina, is renowned for its commitment to advancing healthcare through innovative clinical research. With a strong emphasis on interdisciplinary collaboration, Duke conducts a wide array of clinical trials aimed at developing cutting-edge therapies and improving patient outcomes across various medical fields. The university's Clinical Research Institute provides comprehensive support for trial design, implementation, and regulatory compliance, ensuring that all research adheres to the highest ethical and scientific standards. Duke’s dedication to translating research findings into effective clinical practices underscores its role as a pivotal contributor to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Durham, North Carolina, United States
Patients applied
Trial Officials
Christina Barkauskas, MD
Study Chair
Duke Clinical Research Institute
Susan Redline, MD MPH
Study Chair
Brigham and Women's Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported